drugset / Trial / NCT00385775
Study of XIAP Antisense for Advanced Cancers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to find the maximum tolerated dose, safety and toxicity profile, and to identify any dose limiting toxicities of AEG35156 administered in 2-hour infusions to patients with advanced cancers.
Timeline
- Start
- 2006-06
- Primary completion
- 2008-10
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AEG35156 | Antisense oligonucleotide | 60 mg | Intravenous |